NCT01211691View on ClinicalTrials.gov

Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)

PHASE1/PHASE2SuspendedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

July 31, 2016

Study Completion Date

December 31, 2016

Conditions
Myelodysplastic Syndrome (MDS)Myelofibrosis (MF)
Interventions
DRUG

KB004, Monoclonal Antibody

Trial Locations (9)

3007

Prahran

5000

Adelaide

10029

Manhattan

33136

Miami

33612

Tampa

44195

Cleveland

77030

Houston

94304

Palo Alto

95817

Sacramento

Sponsors

Lead Sponsor

Humanigen, Inc.
All Listed Sponsors
lead

Humanigen, Inc.

INDUSTRY